SGFG
BCRX icon

Silver Grove Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Silver Grove Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150 Buy
+15
New +$136 ﹤0.01% 2277

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Silver Grove Financial Group's BCRX Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 15 shares worth $150. The stake represents ﹤0.01% of the portfolio and ranks #2277 among its holdings.

318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Silver Grove Financial Group held 15 shares of BioCryst Pharmaceuticals worth $150 as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Silver Grove Financial Group position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2277 holding.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.